Lucrative Scenarios Linger over Histopathology Testing Equipment Market with Growing Consumer Preference, says Fact.MR Study

The rapidly advancing diagnostics space has resulted in development of various companies involved in production of diagnostic equipment as well as distribution of testing apparatus and assemblies. The histopathology testing equipment market is no exception, wherein top five companies involved in the development of histopathology testing equipment account for a significant share of the overall market revenue. Top companies such as Thermo Fisher Scientific, Hoffman-la-Roche Ltd., Leica Biosystems, Agilent Technologies Inc., and Merck KGaA collectively account for a revenue share of over 62% in the histopathology testing equipment market.

Request a sample of this premium report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=2240

Increasing awareness regarding cancer screening coupled with higher demand for advanced histopathology testing equipment from diagnostic centers are expected to provide potential avenues of growth for tier 1 manufacturers. These companies are more focused on new product launches, expansion of their current product lines.

They are also involved in acquisitions to expand their current footprint in a bid to enhance their histopathology testing equipment sales channels in the diagnostic space. For instance, in 2017, Agilent Technologies Inc., acquired 100% of the stock of Multiplicom NV, a leading diagnostics company in Europe, in a bid to strengthen Agilent’s presence in the histopathology testing equipment market place by leveraging Multiplicom’s advanced diagnostic kits and testing technology.

Increasing Incidence of Melanoma Fuelling Use of Histopathology Testing Equipment

Increasing incidence of melanoma has been a cause of major concern among individuals. According to United Nations Environment Program, around 200,000 malignant melanoma cases occur every year. Skin Cancer Foundation has revealed that in the past decade (from 2008 till 2018), the number of melanoma cases have increased by about 53 percent annually worldwide.

The demand for histopathological analysis of melanoma has witnessed an increase in the last decade, owing to growing referrals from general practitioners and growing awareness among the general population. These factors have increased the importance of systematic and unified approach toward melanoma histopathology.

Anatomic Pathology Service Providers and Centers to Adopt Histopathological Testing Equipment

Increasing demand for anatomic pathology services on the back of a significant rise in the use of anatomic testing instruments and consumables such as kits is expected to influence the demand for histopathology testing equipment. Anatomic instruments are used to morphologically examine cells and tissues to diagnose chronic diseases at reasonable costs. Recently, anatomic diagnostic centers have been equipped with advanced equipment to carry out effective tissue processing based on histological assessment of samples (H&E preparation) of biopsies that can be carried out in less than 48 hours. This aspect has triggered the use of histopathology sample in turn triggering demand for histopathology testing equipment.

Competitive Landscape

The report on histopathology testing equipment market includes assessment on key players involved in the manufacturing of histopathology testing equipment. Key aspects of histopathology testing equipment market players such as SWOT analysis, product portfolio analysis, innovations and developments, mergers and acquisitions, and key financials are included in the report. The histopathology testing equipment market report covers profiles of key players such as Thermo Fisher Scientific, Hoffman-La-Roche Ltd., and Leica Biosystems.

Companies in the histopathology testing equipment market are largely involved in product development. In 2018, Leica Biosystems has developed rotary microtome solutions that offer superior quality sectioning and improved user safety. The company has also launched next generation BOND-III ISH and IHC stainers. Likewise, Roche Diagnostics has launched VENTANA DP 200, a digital pathology device that connects with VENTANA iScan HT and iScan Coreo.

Companies in the histopathology testing equipment market are also involved in strategic alliances and acquisitions. For instance, Bio-Techne has signed an agreement to acquire Exosome Diagnostics with which Bio-Techne can enhance its position in the histopathology testing equipment space, particularly in the rapidly expanding non-invasive liquid biopsy.  

In June 2018, Merck KGaA entered into an agreement with HistoCyte Laboratories Ltd., to sell products for in situ hybridization and immunohistochemistry. Under this agreement, Merck will deploy its sales expertise to market HistoCyte’s pathology slide controls in the US market and other geographies. This strategic collaboration will also enhance HistoCyte’s global reach in histopathology testing equipment space, particularly in the US market by leveraging Merck’s leadership.

Ask to our Industry Expert @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=2240

Contact Us

Fact.MR

11140 Rockville Pike

Suite 400

Rockville, MD 20852

United States

Email: sales@factmr.com

Web: https://www.factmr.com/

Blog: https://factmrblog.com/

Read Industry News at - https://www.industrynewsanalysis.com/

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

This release was published on openPR.